STAGE IIIB LUNG CANCER AJCC V8

This study tests whether giving two immunotherapy drugs (cemiplimab and fianlimab) before surgery can kill more tumor cells in people with stage IB to IIIB non-small cell lung cancer. About 60 adults will receive the drug combination before their tumor is removed. The goal is to …

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after lung cancer surgery helps people with stage II to IIIB non-small cell lung cancer live longer without the cancer coming back. About 1,210 participants will receive either the combi…

This study tests whether giving the immunotherapy drug durvalumab after surgery can help prevent early-stage non-small cell lung cancer from returning. About 306 people who have had their lung cancer completely removed will either receive durvalumab or be watched closely with no …

This study looks at whether giving chemotherapy and immunotherapy both before and after surgery is better than giving it only after surgery for people with stage II to IIIB non-small cell lung cancer that can be removed. About 1,100 adults will be randomly assigned to one of the …

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests whether adding bevacizumab to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 300 adults with stage IIIB or IV non-squamous non-small cell lung cancer will be randomly assigned to re…

This study tests whether adding chemotherapy to immunotherapy (pembrolizumab) works better than immunotherapy alone for adults aged 70 and older with advanced non-small cell lung cancer. The goal is to see which approach helps patients live longer and keeps the cancer from growin…

This study is for people with stage III non-small cell lung cancer whose disease has gotten worse after standard chemoradiation and immunotherapy. It tests whether adding local treatments like surgery or radiation along with the immunotherapy drug durvalumab can help control the …

This study tests whether the drug canakinumab can prevent lung cancer in 50 people who have suspicious lung nodules that haven't gone away. Participants receive the drug and are monitored for nodule shrinkage, cancer development, and side effects. The goal is to see if this appro…

This study tests whether doing special breathing exercises for several weeks before lung cancer surgery can lower the risk of problems like pneumonia and breathing trouble after the operation. About 220 adults with stage I to IIIB lung cancer will either do the exercises or recei…

This study tests a method called adaptive radiation planning for people with stage II to IV non-small cell lung cancer. Normally, radiation plans stay the same throughout treatment, but tumors can shrink, causing radiation to hit healthy tissue. By updating the plan at set times,…

This study tests whether a yoga program designed for both patients and their family caregivers can improve physical function, fatigue, sleep, and quality of life. It includes 400 people with lung or esophageal cancer who are getting radiation therapy, plus their caregivers. Parti…

This study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track 100 patients to see if tailoring treatment based on individual risk can reduce heart damage. The goal is to learn more about heart risks and improve safety without ch…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung, or genitour…

This study looks at how biomarkers (like DNA from tumors in the blood) can help doctors predict which patients with advanced non-small cell lung cancer will respond to immunotherapy. It involves 535 participants and aims to use these markers to personalize treatment, especially w…